Your browser doesn't support javascript.
loading
Multidisciplinary transcatheter aortic valve replacement heart team programme improves mortality in aortic stenosis.
Jones, Dylan R; Chew, Derek P; Horsfall, Matthew J; Chuang, Anthony Ming-Yu; Sinhal, Ajay R; Joseph, Majo X; Baker, Robert A; Bennetts, Jayme S; Selvanayagam, Joseph B; Lehman, Sam J.
Afiliação
  • Jones DR; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Chew DP; Faculty of Medicine, Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia.
  • Horsfall MJ; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Chuang AM; Faculty of Medicine, Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia.
  • Sinhal AR; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Joseph MX; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Baker RA; Faculty of Medicine, Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia.
  • Bennetts JS; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Selvanayagam JB; Cardiology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
  • Lehman SJ; Cardiac and Thoracic Surgery, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Open Heart ; 6(2): e000983, 2019.
Article em En | MEDLINE | ID: mdl-31413842
Objectives: To analyse the effect of the implementation of a transcatheter aortic valve replacement (TAVR) and multidisciplinary heart team programme on mortality in severe aortic stenosis (AS). Methods: A retrospective, observational cohort study was performed using the echocardiography, cardiothoracic surgery and TAVR databases between 1 January 2006 and 31 December 2016. Outcomes were compared between the pre- and post-TAVR programme eras in a tertiary referral centre providing transcatheter and surgical interventions for AS.All-cause mortality within 5 years from diagnosis was determined for 3399 patients with echocardiographically defined severe AS. Results: Of 3399 patients, there were 210 deaths (6.2%) at 30 days and 1614 deaths (47.5%) at 5 years.Overall, patients diagnosed in the post-TAVR programme era were older, with a lower ejection fraction and more severe AS, but were less comorbid.Among 705 patients undergoing intervention, those in the post-TAVR programme era were older, with a lower ejection fraction and more severe AS but no significant differences in comorbidities.Using an inverse probability weighted cohort and a Cox proportional hazards model, a significant mortality benefit was noted between eras alone (HR=0.86, 95% CI 0.77 to 0.97, p=0.015). When matching for age, comorbidities and valve severity, this benefit was more evident (HR=0.82, 95% CI 0.73 to 0.92, p=0.001).After adjusting for the presence of aortic valve intervention, a significant benefit persisted (HR=0.84, 95% CI 0.75 to 0.95, p=0.005). Conclusion: The implementation of a TAVR programme is associated with a mortality benefit in the population with severe AS, independent of the expansion of access to intervention.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Open Heart Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Open Heart Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália